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Glucose-stimulated insulin secretion is the hallmark of
the pancreatic b-cell, a critical player in the regulation of
blood glucose concentration. In 1974, the remarkable
observation was made that an efflux of intracellular in-
organic phosphate (Pi) accompanied the events of stim-
ulated insulin secretion. The mechanism behind this
“phosphate flush,” its association with insulin secretion,
and its regulation have since then remained a mystery.
We recapitulated the phosphate flush in theMIN6m9b-cell
line and pseudoislets. We demonstrated that knockdown
of XPR1, a phosphate transporter present in MIN6m9 cells
and pancreatic islets, prevented this flush. Concomitantly,
XPR1 silencing led to intracellular Pi accumulation and
a potential impact on Ca21 signaling. XPR1 knockdown
slightly blunted first-phase glucose-stimulated insulin se-
cretion in MIN6m9 cells, but had no significant impact on
pseudoislet secretion. In keeping with other cell types,
basal Pi efflux was stimulated by inositol pyrophosphates,
and basal intracellular Pi accumulated following knock-
down of inositol hexakisphosphate kinases. However, the
glucose-driven phosphate flush occurred despite inositol
pyrophosphate depletion. Finally, while it is unlikely that
XPR1 directly affects exocytosis, it may protect Ca21
signaling. Thus, we have revealed XPR1 as the missing
mediator of the phosphate flush, shedding light on a 45-
year-old mystery.
Glucose-stimulated insulin secretion is the central func-
tion of the pancreatic b-cell for which loss or malfunction
contributes to type 1 and type 2 diabetes, respectively. An
observation made more than 40 years ago by Freinkel et al.
(1) and confirmed in several further studies (2) was that
this glucose-stimulated release of insulin was accompanied
by an efflux of [32P]-labeled inorganic phosphate (Pi) in
pancreatic islets prelabeled with [32P]Pi. This “phosphate
flush” was shown to be specific to pancreatic b-cells (3) and
did not occur in other islet cells or the exocrine pancreas (3).
The efflux occurred simultaneously with first-phase insulin
release (1) but was not driven by the Ca21 influx that
accompanies insulin secretion (1,2). It was a dose-dependent
phenomenon (4) and specific for D- over L-glucose (5) but
could be promoted by a number of other insulin secretagogues
(2). The source of this Pi was identified as existing under the
plasma membrane (6). Over the last 45 years, there have been
a number of proposals advanced to explain the phosphate
flush but the presumed Pi transporter mediating this effect
has not been identified, and thus, there are many unresolved
questions surrounding this phenomenon. Pi metabolism has
specific importance in pancreatic b-cells, as Pi is required for
glycolysis and thus the operation of the b-cell as a glucose
sensor (7). Furthermore, plasma buildup of Pi in, for example,
chronic kidney disease could be detrimental to b-cell viability
(8). Thus, the control of Pi is of central importance to the
b-cell’s ability to maintain blood glucose homeostasis.
Studies in plants have revealed that a number of dif-
ferent Pi transporters possess an SPX domain, named after
proteins Syg1, Pho81, and XPR1 (9). In the mammalian
genome, XPR1 is the only protein that possesses the SPX
domain. XPR1 was originally characterized as a receptor
for xenotropic and polytropic murine retroviruses (10).
However, new studies have revealed XPR1 as the first Pi
efflux transporter to be identified in metazoans (11–14).
In addition, inositol pyrophosphates, which play a central
role in b-cell regulation (15,16), are proposed to specifically
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bind and activate SPX domains, including that of XPR1
(17–19). XPR1 is therefore the first potential candidate
mediating the phosphate flush. Using a pancreatic b-cell
line and a primary b-cell model, we tested the hypothesis
that XPR1 is responsible for the phosphate flush and
studied its regulation by inositol pyrophosphates. We
demonstrate that XPR1 is important for the regulation of
intracellular Pi in the b-cells and is indeed the missing
player that mediates the phosphate flush.
RESEARCH DESIGN AND METHODS
All animal experiments were approved by the Animal Ethics
Committee of Northern Stockholm, Sweden, and carried out
in accordance with the National Institutes of Health’s Guide
for the Care and Use of Laboratory Animals.
Materials
Cell culture reagents, Hanks’ balanced salt solution, M-PER
Mammalian Protein Extraction Reagent, Pierce BCA Pro-
tein Assay, Lipofectamine 2000 and RNAiMAX, TaqMan
gene expression assays, and siRNAs were obtained from
Thermo Fisher Scientific (Stockholm, Sweden). Silencing
was implemented by IP6K siRNAs (15,16) or XPR1 siRNAs
(identification numbers s72989 and s201933) with silencer
select negative control 1 (catalog number 4390843).
Common chemicals, Accutase, and N2-(m-Trifluorobenzyl),
N6-(p-nitrobenzyl) purine (TNP) were from Sigma-Aldrich
(Stockholm, Sweden) or Merck KGaA (Darmstadt, Ger-
many). Carrier-free [32P]orthophosphate and the insulin
AlphaLISA assay were obtained from PerkinElmer (Stock-
holm, Sweden). PiColorLock malachite green–based Pi
assay was obtained from Expedeon/Abcam (Cambridge,
U.K.).
Cell Culture and RNA Silencing in MIN6m9 Cells
MIN6m9 cells (20) were cultured in complete DMEM and
silenced 24 h after seeding as described previously (15,16).
Preparation and RNA Silencing of Pseudoislets
Islets were isolated by collagenase digestion from the pan-
creata of male C57BL/6J mice and immediately extracted
for RNA analysis or cultured in complete RPMI medium
with 10% FBS (16). The following day, the islets were
washed with Hanks’ balanced salt solution and dissociated
into cells using 100 mL Accutase/tube containing ;200
islets in a ThermoMixer shaker (Eppendorf, Göteborg,
Sweden) at 500 rpm and 37°C for 10 min, followed by
gentle pipetting. Then, fresh Accutase (200 mL) was added,
and the step was repeated. Cells were transferred by cen-
trifugation (180g for 8 min) to complete DMEM without
antibiotics and counted. The siRNAs were premixed with
Lipofectamine RNAiMAX in Opti-MEM for 5min. This was
added to the cell suspension (10-fold dilution). After 5
min, the cell suspension was distributed (200mL/well) into
PerkinElmer CellCarrier Spheroid ULA 96-well microplates
(2,500 cells, 10 pmol siRNAs, and 0.6mL RNAiMAX in each
well). After plate centrifugation (180g for 6min), cells were
allowed to reaggregate into three-dimensional struc-
tures (;1 pseudoislet/well) for ;5 days in a cell-culture
incubator.
RNA Extraction and Real-time RT-PCR
Total RNAs were extracted from MIN6m9 cells, islets, or
pseudoislets (RNeasy Mini and Micro kits; Qiagen, Sol-
lentuna, Sweden) and reverse transcribed as previously
described (15,16). The relative expression of mRNA was
measured by real-time RT-PCR TaqMan Gene Expression
Assays: XPR1 (Mm00495501_m1), IP6K1 (Mm00501996_
m1), and IP6K2 (Mm01232057_m1) using ABI 7300 in-
strument and QuantStudio 5 (Thermo Fisher Scientific).
18S rRNA (TaqMan rRNA Control Reagent) was used as
endogenous control.
Dynamic Incubation Assay
MIN6m9 cells were incubated at 37°C in dynamic assays as
described previously (16) in order to determine either Pi
efflux or insulin secretion (see detailed protocols in Sup-
plementary Fig. 1A). The cells were incubated for 90 min
with 25–50 mCi carrier-free [32P]Pi (for Pi efflux measure-
ments) or without this label (for measurements of insulin
secretion) in modified Krebs buffer containing 5.5 mmol/L
glucose. After additional 60 min in unlabeled Krebs buffer
with 0.5 mmol/L glucose, the cell monolayers were sub-
jected to the dynamic phase, exchanging buffer every
minute. The radioactivity of the collected dynamic assay
samples and the total cellular material was determined
using a liquid scintillation counter. Insulin was determined
by the AlphaLISA assay and normalized with total protein,
extracted using M-PER Mammalian Protein Extraction
Reagent, and determined by the BCA Protein Assay. For
determining the intracellular Pi content, cells were
extracted with 5% perchloric acid (PCA) at the time point
indicated in Supplementary Fig. 1B.
Static Incubation Assay
For the determination of Pi efflux, pseudoislets were in-
cubated at 37°C in a similar regimen as the MIN6m9 cells
in the presence of [32P]Pi in modified Krebs buffer with
5.5 mmol/L glucose for 90 min. [32P]Pi was omitted in the
experiments for measuring insulin secretion and intracel-
lular Pi (see protocol in Supplementary Fig. 1C). After
50 min in 3 mmol/L glucose, the pseudoislets were sub-
jected to the static incubation phase (i.e., basal incubation
at 3 mmol/L glucose for 10 min followed by stimulation
with 16.7 mmol/L glucose for 10 min). [32P]Pi and insulin
were determined in the samples by scintillation counting
and the AlphaLISA assay, respectively. PCA extraction of
the pseudoislets was performed to obtain both total in-
tracellular Pi and cellular protein.
Measurements of Intracellular Pi
Intracellular Pi was PCA extracted from cells or pseudois-
lets by modifying an existing procedure (18) to recover the
cellular protein (Supplementary Fig. 1B and C). Measure-
ments of Pi were carried out using the PiColorLock assay
112 The Phosphate Flush Revisited Diabetes Volume 70, January 2021
and total protein was determined by the BCA Protein
Assay.
Measurements of Intracellular Free Calcium
Concentrations
Pseudoislets were loaded with 2 mmol/L Fura-2 LeakRes
(AM) (TEFLabs, Inc., Austin, TX) in modified Krebs buffer
containing 3 mmol/L glucose for 60 min. After loading,
a single pseudoislet was transferred to an open perifusion
chamber maintained at 37°C. The pseudoislet was peri-
fused with Krebs buffer containing 3 mmol/L glucose and
16.7 mmol/L glucose was used for stimulation. Intracel-
lular free calcium concentration ([Ca21]i) was measured as
the 340/380 nm fluorescence ratio using a Spex Fluorolog
spectrophotometer coupled to a Zeiss Axiovert 35M mi-
croscope with a Zeiss Fluar 403/1.30 oil immersion ob-
jective (Carl Zeiss, Göttingen, Germany).
Statistical Analysis
The data, expressed as means 6 SEM, were statistically
analyzed with GraphPad Prism software version 5.0.
Details of analyses are indicated in figure legends, text, and
Supplementary Table 1.
Data and Resource Availability
The data sets generated during and/or analyzed during the
current study are available from the corresponding authors
on reasonable request.
RESULTS AND DISCUSSION
In the original studies, it was shown that in pancreatic
islets, only the b-cells mediated the phosphate flush (3). In
order to investigate this phenomenon, we sought to use
a currently established glucose-responsive b-cell line from
mouse (MIN6m9), as it is a more experimentally amenable
system. MIN6m9 cells are a good b-cell surrogate, both in
terms of their response to glucose and the regulation of
Figure 1—Determination of the phosphate flush and of insulin
secretion in the pancreatic MIN6m9 b-cells. A: Cells were first
labeled for 90 min with 25–50 mCi of carrier-free [32P]Pi in a modified
Krebs buffer containing 5.5 mmol/L glucose and then preincubated
in Krebs buffer with 0.5 mmol/L glucose for 1 h. Next, this buffer was
exchanged, every minute, for 30 min, followed by stimulation with
10 mmol/L glucose at the time indicated, again exchanging solution
every minute. Samples, consisting of the exchanged buffer, were
collected from the final 5 min of the basal glucose (0.5 mmol/L) to the
end of the experiment, and their radioactivity was determined in
a scintillation counter. A more detailed protocol is available in
Supplementary Fig. 1A. Data are means 6 SEM; n 5 4. B: Quan-
tification of the total glucose-stimulated phosphate efflux in A was
obtained by initially averaging the first five points of each experiment
(1–5 min, basal glucose). This value was then subtracted from each
of the 10 points (6–15 min) under glucose stimulation. The resulting
values were then added together; means 6 SEM; n 5 3. *P , 0.05,
one-sample t test.C: In parallel experiments to the one on phosphate
flush shown in A, samples were taken for measurement of insulin
secretion. Data are means 6 SEM; n 5 6. D: Quantification of the
total glucose-stimulated insulin release in experiment shown in C
was obtained by subtracting the average basal insulin secretion in
each experiment (1–5 min) from the insulin secretion under 10-min
glucose stimulation, as described for phosphate efflux; means 6
SEM; n 5 6. *P , 0.05, one-sample t test. The n value denotes
number of independent experiments. E: Illustration hypothesizing
the potential role of XPR1 in b-cell phosphate flush. The SPX domain
is proposed to have a regulatory function. 0.5G, 0.5 mmol/L glucose;
10G, 10 mmol/L glucose; c.p.m., counts per minute.
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Figure 2—Evaluation of the role of XPR1 in pancreaticb-cell phosphate flush, insulin secretion, and [Ca21]i responses.A: Expression of XPR1
mRNA in MIN6m9 cells and islets from C57BL/6J mice; means 6 SEM; n 5 3 and n 5 5 preparations, respectively. Efficiency of XPR1
silencing in MIN6m9 cells (B) and C57BL/6J mouse pseudoislets (C ) treated with siRNAs. The reduction in XPR1 mRNA is expressed as
percentage relative to control siRNA;means6SEM. *P, 0.05, 95%CI. Experiments inD, E,G, andHwere carried out in MIN6m9 cells using
the dynamic incubation protocol described in Fig. 1 and Supplementary Fig. 1A. D: Glucose-stimulated phosphate flush is lost following
XPR1 knockdown. [32P]Pi efflux is normalized to total [
32P] in dish; means6 SEM; n5 4. *P, 0.05, **P, 0.01, ***P, 0.001, two-way ANOVA
with Bonferroni post-test (see Supplementary Table 1). Note: a reduction in [32P]Pi efflux with XPR1 knockdown is apparent under basal
conditions if basal values are normalized to protein: control siRNA, 5.86 1.3 counts per minute (cpm)/mg; XPR1 siRNA, 2.06 0.65 cpm/mg;
means6SEM; n5 4.P, 0.05, Student t test. E: Quantification of the total phosphate flush under glucose stimulation in XPR1 siRNA–treated
cells vs. control siRNA-treated cells in D; means 6 SEM; n 5 4. **P , 0.01, Student t test (for the calculations, see Fig. 1B). F:
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exocytosis (16,21). We first determined that the phosphate
flush occurred in this cell model. Thus, we prelabeled
MIN6m9 cells with carrier-free [32P]Pi using similar pro-
tocols to the original studies in islets (1). This was followed
by a dynamic incubation assay (16,21) that allows us to
assess temporal changes in Pi release and insulin secre-
tion in response to glucose with a 1-min time resolution
(Supplementary Fig. 1A). Figure 1A and B illustrate that
glucose stimulation of these cells leads to the expected
enhanced efflux of [32P]Pi, as well as to an increase in
insulin secretion (Fig. 1C and D).
Intracellular Pi in the MIN6m9 cells cultured in com-
plete DMEM was 41.3 6 1.9 pmol Pi/mg protein (mean 6
SEM; n 5 6), which is comparable to other cells (18,19).
However, it has been reported that intracellular Pi accu-
mulates during the low-glucose condition used to achieve
basal insulin secretion (22). Under these settings (Supple-
mentary Fig. 1B), we also observed an accumulation of Pi
(107.7 6 13.0 pmol Pi/mg protein; n 5 6). This accumu-
lation was significantly reduced (50.96 16.1%; n5 6; P,
0.05, one-sample t test) by maintaining high glucose (10
mmol/L) during the preincubation period. Thus, the phos-
phate flush is a possible mechanism normalizing intracel-
lular Pi during glucose stimulation to avoid reaching very
high levels associated with b-cell dysfunction (8).
We hypothesized that XPR1 plays a crucial role in Pi
efflux in b-cells, mediating the phosphate flush (Fig. 1E).
We detected XPR1 mRNA expression in both MIN6m9
cells and mouse pancreatic islets (Fig. 2A). We then used
siRNA silencing to knockdown the expression of XPR1 in
MIN6m9 cells to ;30% of its normal level (Fig. 2B). This
treatment did not affect either the cell number or the cell
viability (Supplementary Fig. 2). We then used the dynamic
assay to assess the effect of silencing XPR1 on the phos-
phate flush. In this case, we normalized the Pi efflux to the
total phosphate in the cells in order to control for any
disturbance to phosphate metabolism mediated by the
silencing. Figure 2D and E show that knockdown of XPR1
dramatically reduced the glucose-stimulated Pi efflux to
;10% of the control value. Normalizing Pi efflux to pro-
tein revealed that XPR1 also significantly impacted basal Pi
efflux (Fig. 2, legend).We then used pseudoislets, a primary
b-cell model in which we exploited the siRNA approach
and reached a similar level of XPR1 knockdown as in
MIN6m9 cells (Fig. 2C). A consequent reduction of the
phosphate flush was observed (Fig. 2F). Consistent with
the decrease in Pi efflux, intracellular Pi concentrations
were significantly enhanced upon XPR1 silencing, both in
MIN6m9 cells and pseudoislets (Fig. 2M). Thus, XPR1 is
responsible for the b-cell glucose-stimulated phosphate
flush.
An important question, unresolved in previous studies
(2), is whether or not the phosphate flush is necessary for
insulin secretion or is simply a parallel phenomenon that
accompanies exocytosis. Indirect evidence suggested that
the two processes could be disassociated. For example,
removal of extracellular Ca21 or blockade of its entry
prevents insulin release but not the phosphate flush (1,2).
Conversely, stimulation of secretion by sulphonylureas
does not increase the phosphate flush (7). With the iden-
tification of XPR1 as the mediator of the flush, we could,
for the first time, test directly the relationship between the
phosphate flush and insulin exocytosis. Using identical
conditions to those used to assess the phosphate flush, we
measured the impact of XPR1 silencing on insulin release.
Figure 2G and H show only a modest impact on first-phase
insulin secretion under conditions in which the phosphate
flush is almost ablated in MIN6m9 cells. XPR1 knockdown
in pseudoislets did not significantly impact the five-fold
increase in insulin secretion provoked by 10 min of glucose
stimulation (Fig. 2I). Taken together, these data suggest
that the XPR1-mediated phosphate flush is not essential
for insulin secretion.
Freinkel (2) originally proposed that an interaction
between Ca21 ions and the phosphate flush could contrib-
ute to biphasic insulin secretion. Interestingly, several re-
ports have highlighted the relationship of XPR1-mediated
Pi efflux to cellular calcium metabolism (12–14), includ-
ing calcification due to Pi buildup and calcium phosphate
precipitation (13,14). We therefore examined the glucose-
induced changes in [Ca21]i in pseudoislets in which XPR1
was knocked down (Fig. 2J and K). If XPR1 was preventing
calcium phosphate precipitation, we might anticipate a
blunted [Ca21]i response in its absence. There was no
Glucose-stimulated phosphate flush is reduced in pseudoislets following XPR1 knockdown in comparison with control siRNA–treated
pseudoislets; means6 SEM; n5 4. **P, 0.01, Student t test. G: The effect of XPR1 knockdown on glucose-stimulated insulin release was
assessed in parallel experiments to the one in D and E; means 6 SEM; n 5 4, two-way ANOVA. *P , 0.05 with Bonferroni post-test
(Supplementary Table 1). H: Quantification of total insulin secretion under glucose stimulation in the experiment shown in G; means6 SEM;
n 5 4. *P , 0.05, Student t test (for the calculations, see Fig. 1D). I: Glucose-stimulated insulin release is not significantly affected following
XPR1 knockdown in pseudoislets. Insulin secretion induced by stimulation with 16.7 mmol/L glucose for 10 min is expressed as percentage
of basal secretion at 3 mmol/L glucose for 10 min. Basal secretion was also unaffected by XPR1 silencing (control siRNA, 38.66 3.3, XPR1
siRNA, 41.66 10.1 insulin secretion, pg/mg protein). Data are means6 SEM; n5 5; P5 NS, Student t test. J–L: Impact of XPR1 knockdown
on glucose-stimulated increases in [Ca21]i in pseudoislets. J: Example of [Ca
21]i trace of control siRNA–treated pseudoislets. K: Example of
[Ca21]i trace of XPR1 siRNA–treated pseudoislets. L: Quantification of glucose-stimulated increases in [Ca
21]i, expressed as delta change in
Fura-2 340/380 ratio, in control siRNA–treated pseudoislets vs. XPR1 siRNA–treated pseudoislets; n5 6–7;P5NS, Student t test.M: Impact
of XPR1 knockdown on total intracellular Pi, which was determined with the PiColorLock assay in MIN6m9 cells or pseudoislets at the time
points indicated in Supplementary Fig. 1B andC. Data are expressed as percentage of the corresponding control siRNA after normalization to
total protein; means 6 SEM; n 5 3 (MIN6m9 cells) or n 5 5 (pseudoislets). *P , 0.05, Student t test. The n value denotes number of
independent experiments. 0.5G, 0.5 mmol/L glucose; 3G, 3 mmol/L glucose; 10G, 10 mmol/L glucose; 16.7G, 16.7 mmol/L glucose.
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significant impact on the glucose-stimulated Ca21 transient
of XPR1 knocked down pseudoislets compared with controls
(Fig. 2J–L). However, a subsequent stimulation by 25
mmol/L potassium, which drives a higher peak increase in
[Ca21]i, led to a significantly reduced increase in [Ca
21]i in
the XPR1 knocked down pseudoislets (D Fura-2 ratio;
control siRNA–treated, 0.7166 0.049; XPR1 siRNA–treated,
0.5446 0.022, means6 SEM; n5 6–7; P, 0.05, Student
t test). These data suggest that under superphysiological
conditions or prolonged stimulation, the XPR1-mediated
phosphate flush could serve to prevent calcium phosphate
precipitation also in pancreatic b-cells, thus protecting the
Figure 3—Phosphate efflux is regulated by inositol pyrophosphates. A: Scheme illustrating the formation of inositol pyrophosphates and the
use of either siRNA or the pharmacological pan-IP6K inhibitor, TNP, to reduce inositol pyrophosphate formation. B: Impact of combined
siRNA knockdown of IP6K1 and IP6K2 on phosphate flush compared with control siRNA in MIN6m9 cells. [32P]Pi efflux is normalized to total
[32P] in dish; means6 SEM; n5 4, (there was an overall significant impact on phosphate efflux when IP6K1 and IP6K2 were knocked down.
***P, 0.0001, two-way ANOVA, Supplementary Table 1). C: Quantification of total phosphate flush under glucose stimulation in IP6K1 and
IP6K2 siRNA-treated cells and controls in the experiments illustrated in B. There was an overall significant increase in phosphate flush
following IP6K1 and IP6K2 knockdown; means 6 SEM; n 5 4. *P , 0.05, Student t test (for calculations, see Fig. 1B). D: Impact of TNP or
vehicle (DMSO) on phosphate flush in MIN6m9 cells. The inhibitor TNP, or vehicle, was added for the last 30 min of the preincubation and
during the subsequent steps. [32P]Pi efflux is normalized to total [
32P] in dish, (there was an overall significant impact of TNP on phosphate
efflux. ***P , 0.0001, two-way ANOVA, with significant differences at two distinct times; means 6 6 SEM; n 5 4. *P , 0.05, **P , 0.01,
Bonferroni post-test, Supplementary Table 1). To quantify impact of TNP on basal secretion, the first five basal points of the dynamic protocol
were averaged for each experiment ([32P]Pi/total [
32P]): DMSO, 0.00366 0.00027; TNP, 0.00116 0.00023; means6 SEM; n5 4. P, 0.0005,
Student t test. E: Quantification of total phosphate efflux under glucose stimulation in TNP- and DMSO-treated cells in the experiments
showed in D; means 6 SEM; n 5 4. P 5 NS, Student t test (for calculations, see Fig. 1B). F: Impact of IP6K112 knockdown on total
intracellular Pi, whichwas determinedwith the PiColorLock assay inMIN6m9 cells at the time points indicated in Supplementary Fig. 1B. Data
are expressed as percentage of the corresponding control siRNA after normalization to total protein; means6SEM; n5 6. *P, 0.05, Student
t test. The n value denotes number of independent experiments. 0.5G, 0.5 mmol/L glucose; 10G, 10 mmol/L glucose.
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integrity of [Ca21]i signaling, a key driving force of insulin
exocytosis (23,24).
The SPX domain found in XPR1 is regulatory and not
necessary for Pi transport (9,17). Since inositol derivatives
and particularly the inositol pyrophosphates (17) can
specifically bind to SPX domains, it is possible that they
regulate the phosphate flush through this domain (9,17).
We therefore investigated whether inositol pyrophos-
phates have any role in the regulation of the phosphate
flush in MIN6m9 cells, a good b-cell model in studies on
inositol pyrophosphates (15,16). We used two complemen-
tary approaches to curtail the production of the critical
inositol pyrophosphates, 5-diphosphoinositol pentakisphos-
phate (5-PPIP5/5-IP7) and 1,5-bisdiphosphoinositol tetraki-
sphosphate (IP8) (Fig. 3A).
Firstly, we used siRNA to knock down the two IP6Ks
that exist in pancreatic b-cells (IP6K1 and IP6K2) (15,16).
This prevents the production of 5-IP7 and thus also the
formation of IP8 (Fig. 3A). Under these conditions, IP6K1
and IP6K2 are knocked down by ;40% and 50%, re-
spectively, which leads to a 75% reduction in IP7 (15)
(Supplementary Fig. 3A and B). Again, we applied the
dynamic protocol to study the Pi efflux. Reduction in the
levels of IP6K1 and IP6K2 caused a significantly increased
glucose-induced phosphate flush, without affecting basal Pi
efflux (Fig. 3B and C). However, under these conditions, the
expression of XPR1 mRNA was doubled (Supplementary Fig.
4), suggesting a compensatory mechanism for the loss of
the stimulatory inositol pyrophosphates. In addition,
there was an accumulation of intracellular Pi (Fig. 3F), as
reported in other cells in which IP6Ks were knocked
down (18).
We also used a short-term pharmacological approach
applying the pan-specific IP6K inhibitor TNP to circum-
vent the longer-term adaptive responses seen above. This
too blocks the formation of both 5-IP7 and IP8 (Fig. 3A). In
contrast to the long-term knockdown of IP6Ks, TNP re-
duced Pi efflux under basal conditions and delayed the
phosphate flush rise (Fig. 3D and legend). These data show
that acute knockdown of 5-IP7 and IP8 production inhibits
basal phosphate efflux via XPR1, consistent with two
recent reports in other cells (18,19). However, TNP treat-
ment does not reduce the glucose-stimulated phosphate
flush (Fig. 3D and E). It is possible that the acute TNP
treatment leads to a short-term compensatory adaption by
which more existing XPR1 is translocated to the plasma
membrane of b-cells, as observed for active KATP mem-
brane channels upon glucose stimulation (25). Another
factor that could alter Pi efflux kinetics is the buildup of
intracellular Pi that we (Fig. 3F) and others (18) observe on
IP6K knockdown. Furthermore, while our strategy reduces
5-IP7 and IP8, it will not impact a glucose-generated pro-
duction of 1-IP7, which has recently been shown to be
more potent that 5-IP7 in activating XPR1 (19). Thus, we
would suggest that under basal glucose conditions Pi efflux
via XPR1 is directly driven by inositol pyrophosphates.
However, under the glucose stimulatory conditions of the
phosphate flush, other so far unidentified factors linked to
glucose metabolism contribute to a more complex regula-
tion of the XPR1-dependent Pi efflux.
Overall, our study has solved an important aspect of the
b-cell phosphate flush (1). We demonstrate that XPR1 is
the mediator of glucose-stimulated Pi efflux and that this
process is largely independent from inositol pyrophos-
phate regulation. Furthermore, we show that the phos-
phate flush is unlikely to contribute to glucose-stimulated
insulin secretion, while providing a hint that the ultimate
role of this mechanism may be to prevent calcium phosphate
precipitation and thus protect pancreatic b-cell Ca21 signaling.
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